Fas Ligand/TNFSF6 Antibody (MFL4) [FITC] Summary
The immunogen for this antibody was CD95 Ligand.
IgG
Monoclonal
Armenian Hamster
FASLG
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Flow Cytometry Neat
The MFL4 antibody has been tested by flow cytometric analysis of mouse FasL transfected cells and activated T cells. This can be used at less than or equal to 0.5 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS (pH 7.4) and 1.0% BSA
0.09% Sodium Azide
0.1 mg/ml
Protein A or G purified
Notes
For use in analysis use 10 ul of suggested working dilutions for 10^6 cells in 100 ul.
Alternate Names for Fas Ligand/TNFSF6 Antibody (MFL4) [FITC]
- apoptosis (APO-1) antigen ligand 1
- Apoptosis antigen ligand
- APT1LG1CD95L
- APTL
- CD178 antigen
- CD178
- CD95L
- CD95-L
- Fas antigen ligand
- Fas ligand (TNF superfamily, member 6)
- Fas Ligand
- FASLCD95 ligand
- FASLG
- TNFSF6
- TNFSF6FasL
- tumor necrosis factor (ligand) superfamily, member 6
- tumor necrosis factor ligand superfamily member 6
Background
This antibody recognises both mouse and rat CD178, otherwise known as Fas Ligand/ CD95L, a 40kDa type II transmembrane glycoprotein and member of the TNF/NGF superfamily, expressed by activated T cells and NK cells, which can be induced on a variety of cells by radiation, heat shock, chemotherapeutic agents and viral infection. CD178 acts as a key effector of cytotoxicity and in the regulation of immune responses. The binding of CD178 to its receptor CD95 (Fas), induces Fas-mediated apoptosis of target cells, and may be involved in the induction of peripheral tolerance and neutrophil chemotaxis. The binding of decoy receptor 3 (DcR3) to CD178 has been shown to inhibit CD178-mediated apoptosis. Clone MFL4 is reported to block CD178/CD95 induced apoptosis.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
product targets :　Natural Products inhibitors